Celldex Therapeutics Stock
Price
Target price
€36.60
€36.60
1.120%
0.4
1.120%
€51.20
22.04.24 / Tradegate
WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Celldex Therapeutics Stock
Celldex Therapeutics gained 1.120% today.
We see a rather positive sentiment for Celldex Therapeutics with 9 Buy predictions and 1 Sell predictions.
With a target price of 51 € there is a positive potential of 39.34% for Celldex Therapeutics compared to the current price of 36.6 €.
So far the community has only identified positive things for Celldex Therapeutics stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | 1.120% | 0.549% | -5.670% | 11.585% | 1.105% | 58.716% | 589.266% |
| Jaguar Health Inc. | -2.840% | 4.624% | 129.565% | 102.558% | 4.901% | -99.947% | - |
| Vaxart Inc. | -1.080% | -18.881% | -42.777% | 0.718% | 27.909% | -85.688% | - |
| aTyr Pharma Inc | - | 1.351% | -21.466% | -12.791% | 16.279% | -54.268% | -78.399% |
Comments
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $67.00 price target on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) had its price target raised by analysts at Guggenheim from $72.00 to $90.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at TD Cowen. They set an "outperform" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
News
Why Celldex Therapeutics Blasted 13% Higher on Monday
Clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) was a standout on the stock market Monday. The company's share price closed a sturdy 13% higher on the day, thanks to freshly published
